Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aarti Industries Limited (AARTIIND.NS)
Mumbai, IN
Aarti Industries Limited, established in 1984 and headquartered in Mumbai, India, is a prominent manufacturer and supplier of both specialty chemicals and pharmaceutical products. The company's chemical division produces a wide array of compounds including dichlorobenzene, various nitro-chloro and nitro-benzene derivatives, nitro-toluenes, and sulfur, along with other organic and inorganic substances. These crucial materials serve as intermediates for a diverse range of sectors such as agrochemicals, pharmaceuticals, polymer and fuel additives, fast-moving consumer goods (FMCG), dyes, pigments, paints, printing inks, rubber chemicals, and resins. In the pharmaceutical sphere, Aarti Industries develops active pharmaceutical ingredients (APIs) utilized in medications for conditions like hypertension, asthma, cancer, thalassemia, pain relief, ophthalmic disorders, and central nervous system agents, as well as skincare and decongestant products. They also supply pharmaceutical intermediates and a selection of xanthine derivatives, prominently featuring caffeine anhydrous, theophylline, and related compounds. Beyond its manufacturing capabilities, Aarti Industries provides contract manufacturing and research services. The company maintains a significant global presence, exporting its products to approximately 60 countries across North America, Europe, China, Japan, and other international regions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.89% | -5.69% | +10.56% | +0.62% | +17.98% | +25.30% | -0.02% | -6.77% | -37.89% | +326.45% | +49,240.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+16.2% ★ Q1'26: +22.0% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+26.4% ★ Q1'26: +42.6% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-0.2% Q1'26: -1.6% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.2% Q1'26: +9.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+6.6% ★ Q1'26: +8.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.2% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×4.31× Q1'26: 3.69× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 19 Rev. Ana. 21 EPS Ana. |
Mar 2027 18 Rev. Ana. 17 EPS Ana. |
Mar 2028 17 Rev. Ana. 20 EPS Ana. |
Mar 2029 15 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
28.61B
est: 29.23B (-2.1%)
|
29.56B
est: 27.28B (+8.3%)
|
31.15B
est: 29.85B (+4.3%)
|
37.59B
est: 36.43B (+3.2%)
|
41.22B
est: 49.54B (-16.8%)
|
41.05B
est: 45.78B (-10.3%)
|
43.05B
est: 44.81B (-3.9%)
|
51.91B
est: 64.64B (-19.7%)
|
64.92B
est: 67.91B (-4.4%)
|
61.92B
est: 64.49B (-4.0%)
|
71.31B
est: 73.74B (-3.3%)
|
83.62B
77.56B – 88.40B
+13.4% YoY
|
95.93B
89.46B – 105.40B
+14.7% YoY
|
109.40B
94.19B – 125.72B
+14.0% YoY
|
124.21B
111.09B – 139.81B
+13.5% YoY
|
| EBITDA |
4.62B
est: 5.55B (-16.8%)
|
5.70B
est: 2.12B (+168.3%)
|
6.49B
est: 3.74B (+73.3%)
|
7.00B
est: 5.07B (+37.9%)
|
9.60B
est: 6.00B (+60.0%)
|
9.77B
est: 5.43B (+79.9%)
|
9.73B
est: 7.25B (+34.2%)
|
16.87B
est: 8.93B (+88.9%)
|
10.28B
est: 10.50B (-2.1%)
|
9.65B
est: 12.42B (-22.3%)
|
9.78B
est: 13.80B (-29.2%)
|
15.31B
14.20B – 16.18B
+10.9% YoY
|
17.56B
16.38B – 19.29B
+14.7% YoY
|
20.03B
17.24B – 23.01B
+14.0% YoY
|
22.74B
20.34B – 25.59B
+13.5% YoY
|
| EBIT |
3.80B
est: 4.03B (-5.8%)
|
4.71B
est: 3.60B (+31.0%)
|
5.27B
est: 5.17B (+1.8%)
|
5.54B
est: 6.49B (-14.7%)
|
7.97B
est: 7.59B (+5.1%)
|
7.92B
est: 7.29B (+8.5%)
|
7.41B
est: 7.91B (-6.3%)
|
14.41B
est: 9.75B (+47.8%)
|
7.17B
est: 11.46B (-37.4%)
|
5.87B
est: 13.55B (-56.7%)
|
5.44B
est: 9.66B (-43.8%)
|
10.72B
9.94B – 11.33B
+10.9% YoY
|
12.29B
11.46B – 13.51B
+14.7% YoY
|
14.02B
12.07B – 16.11B
+14.0% YoY
|
15.92B
14.24B – 17.92B
+13.5% YoY
|
| Net Income |
2.06B
est: 1.98B (+4.1%)
|
2.57B
est: 1.91B (+34.4%)
|
3.16B
est: 2.80B (+12.7%)
|
3.33B
est: 3.86B (-13.7%)
|
4.92B
est: 4.56B (+7.8%)
|
5.36B
est: 4.47B (+20.0%)
|
5.23B
est: 5.35B (-2.2%)
|
11.86B
est: 6.59B (+79.8%)
|
5.45B
est: 7.76B (-29.7%)
|
4.16B
est: 9.17B (-54.6%)
|
3.31B
est: 3.24B (+2.3%)
|
4.04B
3.35B – 4.93B
+24.8% YoY
|
5.51B
4.13B – 7.16B
+36.3% YoY
|
7.54B
4.77B – 8.87B
+36.8% YoY
|
8.43B
7.27B – 9.81B
+11.9% YoY
|
| SGA |
987.10M
est: 1.74B (-43.2%)
|
1.36B
est: 4.26B (-68.2%)
|
1.69B
est: 4.42B (-61.7%)
|
2.09B
est: 5.83B (-64.1%)
|
2.59B
est: 7.95B (-67.4%)
|
3.22B
est: 6.33B (-49.1%)
|
3.86B
est: 8.79B (-56.1%)
|
3.70B
est: 10.83B (-65.9%)
|
3.89B
est: 12.74B (-69.5%)
|
4.10B
est: 15.06B (-72.8%)
|
4.28B
est: 6.36B (-32.8%)
|
7.06B
6.55B – 7.46B
+10.9% YoY
|
8.10B
7.55B – 8.90B
+14.7% YoY
|
9.23B
7.95B – 10.61B
+14.0% YoY
|
10.48B
9.38B – 11.80B
+13.5% YoY
|
| EPS |
5.81
est: 5.46 (+6.4%)
|
7.71
est: 7.05 (+9.4%)
|
9.61
est: 8.67 (+10.8%)
|
10.24
est: 8.44 (+21.3%)
|
14.18
est: 12.97 (+9.3%)
|
15.38
est: 14.47 (+6.3%)
|
15.02
est: 13.36 (+12.4%)
|
32.71
est: 20.44 (+60.0%)
|
15.04
est: 14.06 (+7.0%)
|
11.49
est: 11.12 (+3.3%)
|
9.14
est: 8.81 (+3.7%)
|
11.13
9.23 – 13.59
+26.4% YoY
|
15.18
11.39 – 19.75
+36.3% YoY
|
20.77
13.14 – 24.45
+36.8% YoY
|
23.24
20.05 – 27.03
+11.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree India Earnings Fund EPI | 0.05% | 1.06M | 0.84% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 1.35M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajendra Vallabhaji Gogri | Chairman & MD | 47M | male |
| Rashesh Chandrakant Gogri | Vice Chairman & MD | 47M | male |
| Ajay Kumar Gupta | Chief Manufacturing Officer & Executive Director | 36M | male |
| Suyog Kalyanji Kotecha | Chief Executive Officer & Executive Director | 36M | male |
| Manoj Murjibhai Chheda | Executive Director | 23M | male |
| Renil Rajendra Gogri | Executive Vice Chairman | 19M | male |
| Chandrakant Vallabhaji Gogri (UDCT Mumbai) | Founder & Chairman Emeritus | 523.9K | male |
| Prashant V. Potnis | Chief Scientific Officer | — | — |
| Chetan Bipin Gandhi | Chief Financial Officer | — | male |
| Bhaskaran Rajagopalan | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AARTIIND.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
